Document Detail

Targeting for cardioplegia: arresting agents and their safety.
MedLine Citation:
PMID:  19492439     Owner:  NLM     Status:  MEDLINE    
Elective temporary cardiac arrest (cardioplegia) is often required during cardiac surgery. In the 1970 s, the development of hyperkalaemic cardioplegic solutions revolutionised cardiac surgery by offering effective chemically-induced cardiac arrest and myocardial protection during global ischaemia. Despite remaining the most widely-used cardioplegic technique, hyperkalaemia can have detrimental effects due to the Na and Ca loading of the cardiac cell induced by depolarisation of the cell membrane. Efforts over the last two decades to establish better cardioplegic agents have mainly remained limited to animal experiments. The failure of these approaches to progress to clinical trials may be due to a lack of clear criteria that a cardioplegic agent should meet at a cellular level and, more importantly, at a system level. In this review we attempt to define the criteria for the optimal cardioplegic agent. We also assess the suitability and clinical potential of previously-studied cardioplegic agents and suggest cellular targets, particularly those involved in cardiac excitation-contraction coupling, that may prove to be attractive options for the development of new cardioplegic drugs. Finally, we propose a multicellular target approach using a combination of pharmacological agents in order to offer better cardioplegic solutions.
Hazem B Fallouh; Jonathan C Kentish; David J Chambers
Related Documents :
17670129 - Comparison of the immediate post-operative outcome of two different myocardial protecti...
3807399 - The st. thomas' hospital cardioplegic solution. a comparison of the efficacy of two for...
15179339 - Myocardial function in early hours after coronary artery bypass grafting in patients wi...
19628529 - Mechanoenergetic function and troponin t release following cardioplegic arrest induced ...
22051849 - Myocardial performance and its acute response to angiotensin ii infusion in fetal sheep...
7671379 - Normothermic continuous antegrade blood cardioplegia does not prevent myocardial edema ...
14522739 - Body mass index and preinfarction angina in elderly patients with acute myocardial infa...
11170319 - Acute stent recoil: in vivo evaluation of different stent designs.
20349199 - Extracorporeal membrane oxygenation as a "bridge to recovery" in a case of myotomy for ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in pharmacology     Volume:  9     ISSN:  1471-4892     ISO Abbreviation:  Curr Opin Pharmacol     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-06-02     Completed Date:  2009-06-23     Revised Date:  2014-02-19    
Medline Journal Info:
Nlm Unique ID:  100966133     Medline TA:  Curr Opin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  220-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcium Channel Agonists / pharmacology
Calcium Channel Blockers / pharmacology
Cardioplegic Solutions / adverse effects*,  pharmacology*
Drug Delivery Systems
Heart Arrest, Induced / methods,  standards*
Potassium Channels / drug effects
Propanolamines / pharmacology,  therapeutic use
Grant Support
G0001112//Medical Research Council
Reg. No./Substance:
0/Calcium Channel Agonists; 0/Calcium Channel Blockers; 0/Cardioplegic Solutions; 0/Potassium Channels; 0/Propanolamines; MDY902UXSR/esmolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Distinct interactions of 2'- and 3'-O-(N-methyl)anthraniloyl-isomers of ATP and GTP with the adenyly...
Next Document:  Consequences of sleep deprivation on neurotransmitter receptor expression and function.